<<TTP>>
I, alas, still hold some TTP. I bought it a long time back, just for iloperidone. (My basis is around $3.50, and I sold a portion at much higher levels, so I suppose I can't complain too much, but it's always hard to see what seemed at one point like a sure 20-bagger dwindle like this).
I feel the key to TTP is still iloperidone. The question is whether the delay suggests a terminal problem or not, and I just don't know. Maybe more will leak out over the next months.
Without iloperidone, TTP is not the sort of stock I typically buy. Spheramine seems neat, but it's a long way from market and best viewed cautiously. I'm also somewhat of a general skeptic on cancer vaccines.
So I will likely wait and see what if anything emerges on iloperidone. There's always the additional chance I'll get lucky and some of their other programs will come up with some good results.
In terms of your analysis, I don't think it would quite regain its former heights even if iloperidone does pan out. The competitive landscape has gotten tougher, and the delay will definitely hurt some. I do agree on your downside guess, though.
Peter |
